Tread Carefully in Choosing the Next FDA Leader
The potential re-appointment of Robert Califf as commissioner is cause for concern
Related Articles
Biomarker Testing in Advanced Cancer Still Lags Behind Guideline Recommendations
Only 35% of patients had any type of biomarker testing to guide use of targeted agents
Biomarker Testing in Advanced Cancer Still Lags Behind Guideline Recommendations
Only 35% of patients had any type of biomarker testing to guide use of targeted agents
Gender-Affirming Care for Minors in FTC’s Crosshairs
Detransitioners and their advocates made their case against doctors, medical societies
Jeffrey A. Berinstein, MD, on the Safety of Pre-Op Tofacitinib in Acute Severe UC
Despite numerous treatments for acute severe ulcerative colitis (ASUC) that effectively reduce both symptom severity and disease complications — including corticosteroids as the current standard…
Opinion | It’s ‘Code Red’ for Medicaid
It’s too late to stop the ‘Big Beautiful Bill’ but it’s not too late to continue the fight
NIH to Cap How Much Journals Can Charge Authors for Open Access
Exact amount still to be determined, agency says
FDA OKs Moderna’s COVID Shot for Kids
It’s the first COVID shot to be fully approved for the youngest children
DOJ Subpoenas Doctors Over Youth Gender Care
Attorney General says those that ‘mutilated children’ will be held accountable
Combo Therapy Boosts Survival in Resectable Biliary Tract Cancer
Chemoradiation plus immunotherapy a winner in Chinese study
FDA Approves Label Change for Alzheimer’s Amyloid Drug
Brain edema risk expected to be less with new donanemab dosing schedule